Loeb JN: The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 15: 189-192,1972
Mikkelsen WN, Dodge HJ, Valkenburg H: The distribution of serum uric acid values in a population unselected as to gout orhyperuricemia; Tecumseh, Michigan1959-1960. Am J Med 39: 242-251,1965
Hakoda M, Masunari N, Yamada M, et al: Serum uric acid concentration as a risk factor for cardiovascular mortality; A longterm cohort study of atomic bomb survivors. J Rheumatol 32: 906-912,2005
Campion EW, Glynn RJ, DeLabry LO: Asymptomatic hyperuricemia; Risks and consequences in the Normative Aging Study. Am J Med 82 :421-426,1987
Lin KC, Lin HY, Chou P: The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27: 1501-1505,2000
川崎拓，七川歓次：住民検診による痛風の疫学調査．痛風と核酸代謝30：66，2006
Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis; Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51: 321-325,2004
Kang EH, Lee EY, Lee YJ, et al: Clinical features and risk factors of postsurgical gout. Ann Rheum Dis 67 :1271-1275,2008
1） Franse LV, Pahor M, Di Bari M, et al : Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program（SHEP）. J Hypertens 18 :1149-1154,2000
2） Verdecchia P, Schillaci G, Reboldi G, et al : Relation between serum uric acid and risk of cardiovascular disease in essential hypertension ; The PIUMA study. Hypertension 36 :1072-1078,2000
3） Wang JG, Staessen JA, Fagard RH, et al : Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 37 :1069-1074,2001
4） Hφieggen A, Alderman MH, Kjeldsen SE, et al ; LIFE Study Group : The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65 :1041-1049,2004
5） Shimamoto K, Fujita T, Ito S, et al ; J-HEALTH Study Committees : Impact of blood pressure control on cardiovascular events in 265,12 Japanese hypertensive patients ; The Japan Hypertension Evaluation with Angiotensin Ⅱ Antagonist Losartan Therapy（J-HEALTH）study, a prospective nationwide observational study. Hypertens Res 31 :469-478, 2008
6） Alderman MH, Cohen H, Madhavan S, et al : Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34 :144-150,1999
7） Ogihara T, Kikuchi K, Matsuoka H, et al ; Japanese Society of Hypertension Committee : The Japanese Society of Hypertension Guidelines for the Management of Hypertension（JSH2009）. Hypertens Res 32 :3-107,2009
8） Iwanaga T, Sato M, Maeda T, et al : Concentration-dependent mode of interaction of angiotensin Ⅱ receptor blockers with uric acid transporter. J Pharmacol Exp Ther 320 :211-217,2007
9） Enomoto A, Kimura H, Chairoungdua A, et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 :447-452,2002
10） Hamada T, Ichida K, Hosoyamada M, et al : Uricosuric action of losartan via the inhibition of urate transporter 1（URAT 1） in hypertensive patients. Am J Hypertens 21 :1157-1162,2008
11） Naritomi H, Fujita T, Ito S, et al : Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension ; The Japan Hypertension Evaluation with Angiotensin Ⅱ Antagonist Losartan Therapy（J-HEALTH）study. Hypertens Res 31 :295-304,2008
タコちゅけ
けいしゅけ
タコちゅけ
記事の感想など，ひとこと頂けますか？